Terminated PHASE1 INTERVENTIONAL 1-arm NCT02606630

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

A [C-11]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT-555 on Central Nervous System Inflammation in Subjects With Relapsing Forms of Multiple Sclerosis

Sponsor: AbbVie

Conditions Multiple Sclerosis

Interventions ABT-555

Updated 6 times since 2017 Last updated: Feb 6, 2017 Started: Oct 31, 2015 Primary completion: Dec 31, 2015 Completion: Dec 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Company decision

Other terminated trials from AbbVie

See all terminations from AbbVie

Other Multiple Sclerosis trials with similar outcome

Browse all Multiple Sclerosis trials

Listed as NCT02606630, this PHASE1 trial focuses on Multiple Sclerosis and remains terminated or withdrawn. Sponsored by AbbVie, it has been updated 6 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

Status: Suspended → Terminated

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Suspended PHASE1

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie

Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom
• Whitechapel, United Kingdom